Today, ACI, along with a coalition of policy groups, filed testimony with the California legislature in opposition to a bill that would institute price controls on restaurant food delivery services. The letter states that the establishment of a price control scheme for contracts between private third-party delivery platforms and restaurants (as proposed under AB 286) […]
Each year, financial merchants such as Visa, Mastercard, American Express, and banks process 39.6 billion card transactions in the United States, amounting to 108.6 million transactions each day. To ensure these transactions are processed quickly and securely, financial merchants and banks impose interchange fees on transactions, more commonly known as swipe fees. Last year, merchants businesses paid financial […]
One of the most pressing problems facing Americans and the U.S. healthcare system is the affordability of prescription drugs. An estimated 58 million Americans face medication insecurity and have “been unable to afford prescribed drugs at least once in the last 12 months.” The Organization for Economic Co-Operation and Development claimed that per capita, Americans pay $1,220 per year […]
ACI joined 74 other groups urging Congress and the President not to adopt drug price controls. You can read the letter online.
ACI joined a coalition to send a letter to Congress in opposition to government price controls on Aluminum. You can read the letter online.
Soaring prescription drug prices are putting financial pressure on families across the country. In response, state legislators are increasingly considering limits on the annual price increase of prescription drugs. But rather than making drugs more affordable, these policies risk reducing consumer access to cheaper, generic alternatives. Read this op-ed in The Hill […]
The proposed Aluminum Pricing Examination Act would empower the U.S. Commodities Futures Trading Commission to impose government pricing controls over aluminum. Our coalition letter explains why these price controls would serve as bad public policy that would erode U.S. supplies and aid foreign producers.
Americans are right to be concerned about the high out-of-pocket costs of pharmaceuticals. But targeting America’s free enterprise system is the wrong solution. Putting bureaucrats abroad in charge of deciding how our drug market operates may save some money now, but it’ll hurt consumers in the long-run. This op-ed, published in Real Clear Health, explains […]
Surprise medical billing needs to end. But we must be skeptical of any proposal that caps rates and opens the door further for socialized medicine. At the same time, our healthcare system cannot afford an overly simplistic and unproven approach that would likely have negative effects on patients, doctors, and hospitals while granting more power […]